Last reviewed · How we verify
Long-Term Varenicline (long-term-varenicline)
Long-Term Varenicline (generic name: long-term-varenicline) is a Varenicline tablet x 24 weeks drug developed by Pfizer Inc.. It is currently in preclinical development.
Varenicline tablet x 24 weeks
Long-Term Varenicline is a partial agonist of the α4β2 nicotinic acetylcholine receptor approved for smoking cessation. It reduces cravings and withdrawal symptoms while blocking the rewarding effects of nicotine by binding to receptors in the brain that nicotine normally activates. Its extended duration of action supports sustained abstinence beyond standard treatment periods.
-
Baseline preclinical → approval rate
+5.0pp
Industry-wide preclinical drugs reach approval ~5% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2036–2040 | — |
| EMA | EU | 2037–2041 | +0.7 yr |
| MHRA | GB | 2037–2041 | +0.7 yr |
| Health Canada | CA | 2037–2042 | +0.9 yr |
| TGA | AU | 2037–2042 | +1.2 yr |
| PMDA | JP | 2037–2042 | +1.5 yr |
| NMPA | CN | 2038–2043 | +2.3 yr |
| MFDS | KR | 2037–2042 | +1.4 yr |
| CDSCO | IN | 2037–2043 | +1.8 yr |
| ANVISA | BR | 2038–2043 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | long-term-varenicline |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Varenicline tablet x 24 weeks |
| Therapeutic area | Other |
| Phase | preclinical |
Mechanism of action
When someone smokes, nicotine floods into the brain and activates specific receptor proteins called α4β2 nicotinic acetylcholine receptors. This activation releases dopamine, the brain's 'reward' chemical, which reinforces the smoking habit and creates cravings when nicotine levels drop. Varenicline works by sitting on these same receptors and partially activating them—enough to ease withdrawal symptoms and reduce cravings, but not as powerfully as nicotine itself. By occupying these receptors, varenicline also blocks nicotine from attaching and activating them fully. This means if someone does smoke while taking the medication, they don't get the strong dopamine rush that normally rewards and reinforces smoking behavior. This dual action—reducing cravings while eliminating the satisfaction from smoking—makes quitting more tolerable and successful. The long-term formulation extends treatment duration beyond the standard 12-week course, providing continued brain-receptor occupancy to sustain cessation benefits and reduce relapse risk. This prolonged support acknowledges that nicotine addiction involves deep brain changes that take time to normalize, and maintaining medication coverage during the critical period when relapse risk remains elevated improves long-term abstinence rates.
Approved indications
Pipeline indications
- Tobacco Use Disorder — preclinical
Common side effects
Key clinical trials
- Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD). (Phase 3)
- Smoking Cessation Program in the Preadmission Clinic (Phase 4)
- An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation (Phase 3)
- Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Ces (Phase 4)
- Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit (Phase 4)
- Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users (Phase 2/3)
- Long-term Varenicline Treatment for Smoking Cessation (Phase 4)
- A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Long-Term Varenicline CI brief — competitive landscape report
- Long-Term Varenicline updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Long-Term Varenicline
What is Long-Term Varenicline?
How does Long-Term Varenicline work?
Who makes Long-Term Varenicline?
What is the generic name of Long-Term Varenicline?
What drug class is Long-Term Varenicline in?
What development phase is Long-Term Varenicline in?
Related
- Drug class: All Varenicline tablet x 24 weeks drugs
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing